Oppenheimer Downgrades AN2 Therapeutics to Perform
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jeff Jones has downgraded AN2 Therapeutics (NASDAQ:ANTX) from Outperform to Perform, indicating a neutral outlook on the stock.

February 12, 2024 | 4:54 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
AN2 Therapeutics downgraded by Oppenheimer from Outperform to Perform, suggesting a shift to a neutral stance on the stock.
The downgrade by a prominent analyst like Jeff Jones from Oppenheimer can influence investor sentiment, potentially leading to a neutral short-term impact on ANTX's stock price. The change from Outperform to Perform suggests that the analyst no longer sees the stock outperforming the market or its sector, which could lead to a period of stability or sideways movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100